Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome
- 1 July 2002
- journal article
- clinical trial
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 76 (3) , 234-242
- https://doi.org/10.1016/s1096-7192(02)00044-6
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Hermansky-Pudlak Syndrome Type 3 in Ashkenazi Jews and Other Non–Puerto Rican Patients with Hypopigmentation and Platelet Storage-Pool DeficiencyAmerican Journal of Human Genetics, 2001
- Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2001
- TGF-β is a critical mediator of acute lung injuryJournal of Clinical Investigation, 2001
- Hermansky-Pudlak Syndrome: Models for Intracellular Vesicle FormationMolecular Genetics and Metabolism, 1998
- Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in miceToxicology Letters, 1997
- Positional cloning of a gene for Hermansky–Pudlak syndrome, a disorder of cytoplasmic organellesNature Genetics, 1996
- Reliability of absent platelet dense bodies as a diagnostic criterion for Hermansky‐Pudlak syndromeAmerican Journal of Hematology, 1987
- Lung function among asbestos cement factory workers: Cross-sectional and longitudinal studyAmerican Journal of Industrial Medicine, 1984
- Hermansky-Pudlak syndromeThe American Journal of Medicine, 1979
- Small Airways in Idiopathic Pulmonary FibrosisJournal of Clinical Investigation, 1977